ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic InitiativesGlobeNewsWire • 03/15/24
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement EquivirGlobeNewsWire • 02/14/24
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New ContractsGlobeNewsWire • 01/23/24
ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern TimeGlobeNewsWire • 11/02/23
ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.GlobeNewsWire • 10/17/23
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.GlobeNewsWire • 08/10/23
ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern TimeGlobeNewsWire • 08/02/23
ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics TechnologiesGlobeNewsWire • 06/22/23
ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023GlobeNewsWire • 06/07/23
ProPhase Labs' Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testingGlobeNewsWire • 06/01/23
ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/11/23
ProPhase Labs hires Dr. Matthew Halpert to Drive Company's Key Therapeutic and Diagnostic Oncology ProgramsGlobeNewsWire • 05/08/23
ProPhase Labs' Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancersGlobeNewsWire • 05/03/23
ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?Zacks Investment Research • 05/03/23
ProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 Most Innovative Healthcare Leaders to Watch in 2023GlobeNewsWire • 04/28/23